According to representatives of the Ministry, proven clinical benefit from transfusion of blood plasma from young donors for treatment, mitigation or prevention of these conditions is not, however, there are risks associated with the use of any products based on plasma.
Plasma, the liquid portion of blood, contains proteins to help the blood clot. The FDA warns that although "bad actors" may be charging thousands of dollars for the treatments, they come with significant risks that include allergic reactions and, more rarely, the transmission of infectious diseases. There's nothing within the FDA's assertion about wholesome methods for unholy, undead Individuals to taper off their consumption of the blood of younger folks, and no sense that anybody within the administration is even contemplating the attainable hurt of forcing them on a crash blood food regimen, not to mention mitigating them. Plasma infusion is an approved use by the FDA in trauma settings or in those whose blood doesn't coagulate.
The FDA said that the promoted benefits of such plasma transfusions had not been clinically proved, and noted that this type of procedure could potentially cause harm.
"We support sound, scientific research and regulation of medical treatments", Gottlieb and Marks said.More news: As U.S. pushes to ban Huawei, UK considers softer approach
More news: Judge tightens gag order on Roger Stone over threatening Instagram post
More news: Claire Williams says team will race in Australia
In their strongly worded statement, the FDA warned that anxious patients "are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies" and that promoting plasma for these unproven purposes could encourage patients not to get the actual medically proven treatments available to them. A major problem with this was not only the inherent risks of getting a blood plasma transfusion from an unknown donor, there is also the lack of human studies that proves this treatment works.
According to HuffPost, Karmazin said he didn't feel FDA approval of his own study of the merits of young plasma therapy was necessary - and the results of the study have never been released.
The FDA said that anyone providing plasma transfusions for a non-FDA-recognized goal should have what's known as an Investigational New Drug (IND) application with the FDA. Jesse Karmazin, the company's founder, has maintained the efficacy of the treatment despite evidence to the contrary.
The statement did not specifically target Ambrosia, but "establishments in several states that are offering infusions of plasma from young donors to purportedly treat the effects of a variety of conditions".
The use of blood products is an active area of aging research. Nevertheless, said Drs. Gottlieb and Marks in a statement, "We're concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies".